Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Change in Accured Expenses (2020 - 2025)

Treace Medical Concepts (TMCI) has disclosed Change in Accured Expenses for 6 consecutive years, with $778000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 83.96% year-over-year to $778000.0, compared with a TTM value of -$2.4 million through Dec 2025, up 69.47%, and an annual FY2025 reading of -$2.4 million, up 69.47% over the prior year.
  • Change in Accured Expenses was $778000.0 for Q4 2025 at Treace Medical Concepts, down from $2.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $9.5 million in Q4 2023 and bottomed at -$6.9 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $547350.0, with a median of $898000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses skyrocketed 783.77% in 2022, then crashed 675.66% in 2024.
  • Year by year, Change in Accured Expenses stood at $5.9 million in 2021, then plummeted by 31.67% to $4.0 million in 2022, then skyrocketed by 136.28% to $9.5 million in 2023, then tumbled by 48.85% to $4.8 million in 2024, then plummeted by 83.96% to $778000.0 in 2025.
  • Business Quant data shows Change in Accured Expenses for TMCI at $778000.0 in Q4 2025, $2.1 million in Q3 2025, and $857000.0 in Q2 2025.